000			02103 a2200577 4500
005			20250517105210.0
264		0	_c20170728
008			201707s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2016.07.013 _2doi
040			_aNLM _beng _cNLM
100	1		_aLin, Hsiao-Hui
245	0	0	_aInhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. _h[electronic resource]
260			_bCancer letters _c10 2016
300			_a58-66 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aApoptosis Regulatory Proteins _xmetabolism
650	0	4	_aBridged Bicyclo Compounds, Heterocyclic _xpharmacology
650	0	4	_aCarcinoma, Hepatocellular _xgenetics
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHep G2 Cells
650	0	4	_aHumans
650	0	4	_aLiver Neoplasms _xgenetics
650	0	4	_aMale
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Nude
650	0	4	_aMyeloid Cell Leukemia Sequence 1 Protein _xmetabolism
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds _xpharmacology
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aPyrimidinones _xpharmacology
650	0	4	_aRNA Interference
650	0	4	_aRNAi Therapeutics
650	0	4	_aSorafenib
650	0	4	_aTransfection
650	0	4	_aWnt Signaling Pathway _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_abeta Catenin _xantagonists & inhibitors
700	1		_aFeng, Wen-Chi
700	1		_aLu, Li-Chun
700	1		_aShao, Yu-Yun
700	1		_aHsu, Chih-Hung
700	1		_aCheng, Ann-Lii
773	0		_tCancer letters _gvol. 381 _gno. 1 _gp. 58-66
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2016.07.013 _zAvailable from publisher's website
999			_c26240236 _d26240236